You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
Synvista Therapeutics Inc.
Headquarters:Montvale, NJ
Year Founded:1986
Status:Archived
Historical deals and financings can be found by searching the organization's name in the BCIQ Deals and Financing Modules*.*desktop version only

BioCentury | Jun 13, 2005

Clinical News

Alagebrium: Phase IIa halted

...months. ALT is awaiting the agency's decision about the Phase IIa PEDESTAL heart failure trial. Alteon...

BioCentury | Feb 02, 2009

Clinical News

SYI-2074: Phase II discontinued

...to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream formulation of the product for Synvista...
...Novel Therapeutic Technologies Inc. , Wilmington, Del. Oxis International Inc. (OTCBB:OXISE; Euronext:OXI), Foster City, Calif. Synvista Therapeutics Inc....

BioCentury | Feb 02, 2009

Clinical News

Alagebrium: Phase II discontinued

...160 patients to evaluate 20 mg of oral alagebrium given twice daily for 6 months. Synvista Therapeutics Inc....

BioCentury | Feb 02, 2009

Clinical News

Alagebrium: Phase II discontinued

...evaluate 200 mg of oral alagebrium given twice daily for 9 months in 102 patients. Synvista Therapeutics Inc....

BioCentury | Jan 19, 2009

Clinical News

Alagebrium: Completed Phase II enrollment

...II BENEFICIAL trial evaluating 200 mg of oral alagebrium given twice daily for 9 months. Synvista Therapeutics Inc....

BioCentury | Jan 12, 2009

Finance

2009 milestones

...data 2009 Synta (NASDAQ:SNTA)/ GSK (LSE:GSK; NYSE:GSK) Elesclomol (formerly STA-4783) Metastatic melanoma Submit NDA 2H09 Synvista...

BioCentury | Jan 05, 2009

Clinical News

CML Assay diagnostic data

...was measured with Synvista's CML Assay. Data were published in the European Journal of Nutrition. Synvista Therapeutics Inc....

BioCentury | Jan 05, 2009

Clinical News

CML Assay diagnostic data

...was measured with Synvista's CML Assay. Data were published in the American Journal of Hypertension. Synvista Therapeutics Inc....

BioCentury | Dec 22, 2008

Clinical News

SYI-2074: Phase II started

...Synvista began a double-blind, placebo-controlled, Israeli Phase II trial of topical SYI-2074 in 30 patients. Synvista...
...to SYI-2074 from Oxis. Novel Therapeutic developed the topical cream formulation of the product for Synvista...
...Novel Therapeutic Technologies Inc. , Wilmington, Del. Oxis International Inc. (OTCBB:OXISE; Euronext:OXIS), Foster City, Calif. Synvista Therapeutics Inc....

BioCentury | Nov 24, 2008

Clinical News

Haptochek regulatory update

...company said diabetic patients with the Hp2-2 genotype have a higher risk of cardiovascular complications. Synvista Therapeutics Inc....

BioCentury | Jun 16, 2008

Clinical News

SYI-2074: Phase II data

...20, 40 or 80 mg of SYI-2074 or placebo 3 times daily for 28 days. Synvista...
...has exclusive rights to SYI-2074 from Oxis. Oxis International Inc. (OTCBB:OXIS; Euronext:OXIS), Foster City, Calif. Synvista Therapeutics Inc....

BioCentury | Jun 16, 2008

Clinical News

SYI-2074: Phase II data

...in diabetic patients undergoing angioplasty. CK-MB is a marker that indicates damage to heart muscle. Synvista...
...has exclusive rights to SYI-2074 from Oxis. Oxis International Inc. (OTCBB:OXIS; Euronext:OXIS), Foster City, Calif. Synvista Therapeutics Inc....

BioCentury | May 19, 2008

Clinical News

Alagebrium: Phase II started

...evaluate 20 mg of oral alagebrium given twice daily for 6 months in 160 patients. Synvista Therapeutics Inc....

BioCentury | Apr 07, 2008

Clinical News

Synvista preclinical data

...College of Cardiology meeting in Chicago. Synvista is developing a test to detect Hp genotype. Synvista Therapeutics Inc....

BioCentury | Feb 14, 2008

Targets & Mechanisms

Cancerous RAGE

...is an interesting article from a reputable group," said Noah Berkowitz, president and CEO of Synvista Therapeutics Inc....
...interfering with RAGE raises the issue of what becomes of AGEs that RAGE ordinarily binds. "Synvista...
...Phase II trials to treat systolic hypertension and diastolic heart failure. In 2005, Synvista (then Alteon...

BioCentury | Jan 28, 2008

Clinical News

ALT-2074: Phase II start

...This year, Synvista will begin an Israeli Phase II trial of topical ALT-2074. The company has...
...has exclusive rights to ALT-2074 from Oxis. Oxis International Inc. (OTCBB:OXIS; Euronext:OXIS), Foster City, Calif. Synvista Therapeutics Inc....

BioCentury | Jan 21, 2008

Company News

NTT, Synvista deal

...Novel will develop a topical cream formulation of ALT-2074 to treat psoriasis for Synvista. Synvista plans...
...II trial (Study 201) to prevent myocardial infarction (MI) in high-risk diabetic patients. Synvista (formerly Alteon...
...Foster City, Calif.) (see BioCentury, April 16, 2007). Novel Therapeutic Technologies Inc. , Wilmington, Del. Synvista Therapeutics Inc....

BioCentury | Nov 19, 2007

Clinical News

Alagebrium: Phase II started

...SYI began the double-blind, placebo-controlled, Dutch Phase II BENEFICIAL trial in 100 patients. Synvista Therapeutics Inc. (SYI), Montvale...

BioCentury | Nov 12, 2007

Clinical News

Haptoglobin type diagnostic diagnostic data

...in a Phase II trial to prevent MI in diabetes patients with the Hp2-2 genotype. Synvista Therapeutics Inc....

BioCentury | Oct 29, 2007

Clinical News

Synvista preclinical data

...reduce diabetes-related gastrointestinal complications. Data on the AGE-crosslink breaker were published in Neurogastroenterology and Motility. Synvista Therapeutics Inc....

BioCentury | Oct 08, 2007

Company News

Synvista management update

Synvista Therapeutics Inc. (SYI), Montvale, N.J. Business: Cardiovascular, Endocrine Hired: Carl Mendel as VP of clinical development and CMO, formerly VP of metabolism projects at sanofi-aventis Group WIR Staff Cardiovascular...

BioCentury | Sep 17, 2007

Company News

Synvista board of directors update

Synvista Therapeutics Inc. (SYI), Montvale, N.J. Business: Cardiovascular, Endocrine Appointed: John Bedard, SVP of worldwide regulatory affairs at MannKind Corp. WIR Staff Cardiovascular...

BioCentury | Jul 30, 2007

Company News

Alteon cardiovascular, endocrine news

...The company changed its name to Synvista Therapeutics Inc. and its ticker to SYI. Alteon Inc. (ALT), Montvale...

BioCentury | Jul 02, 2007

Clinical News

Organoselenium: Phase II started

...placebo-controlled, U.S. Phase II trial (Study 201) in 60 patients with the haptoglobin 2-2 phenotype. Alteon...

BioCentury | Apr 16, 2007

Company News

Alteon, BioRap Technologies Ltd., Oxis deal

...inhibitor, is in Phase II testing to prevent myocardial infarction (MI) in high-risk diabetic patients. Alteon...

BioCentury | Apr 16, 2007

Clinical News

Organoselenium: Phase II start

...Haptoglobin 2-2 genotype. The company got an exclusive license to ALT-2074 from OXIS last week. Alteon...

BioCentury | Feb 26, 2007

Clinical News

Alteon preclinical data

...the Annual Dialysis meeting in Denver. Alagebrium is an Advanced Glycosylation End-product (A.G.E.) crosslink breaker. Alteon...

BioCentury | Nov 20, 2006

Clinical News

Alteon, Oxis preclinical data

...a glutathione peroxidase mimetic. Data were presented at the American Heart Association meeting in Chicago. Alteon...

BioCentury | Oct 30, 2006

Finance

Ebb & Flow

...York as a managing director for healthcare investment banking. Moch was president and CEO of Alteon...

BioCentury | Oct 02, 2006

Clinical News

Alagebrium: Phase II start

...Phase II trial to improve cardiac compliance and diastolic function in about 60 aged individuals. Alteon...

BioCentury | Sep 25, 2006

Tools & Techniques

Tackling RAGE interaction

...Previous attempts with advanced glycosylation endproducts (A.G.E.) have not met with success in other settings. Alteon...

BioCentury | Sep 25, 2006

Clinical News

Alteon preclinical data

...increasing their output in the urine. Data were published in the American Journal of Nephrology. Alteon...

BioCentury | Sep 18, 2006

Company News

MaxCyte management update

...Gene/Cell therapy Hired: Judith Hedstrom as SVP of corporate and business development, formerly COO of Alteon...

BioCentury | May 15, 2006

Company News

HaptoGuard, University of Calgary deal

...glutathione peroxidase mimetics to treat cardiovascular and other inflammatory diseases. HaptoGuard is being acquired by Alteon...

BioCentury | Apr 24, 2006

Company News

Alteon, HaptoGuard deal

...in Phase II testing for heart failure. The acquisition is expected to close next quarter. Alteon...

BioCentury | Apr 20, 2006

Company News

Alteon acquiring HaptoGuard

ALT said it will acquire inflammation and cardiovascular company HaptoGuard (Fort Lee, N.J.) in a stock deal. ALT will issue $5.3 million of stock (about 22.5 million shares) to HaptoGuard shareholders. Also, HaptoGuard shareholders will...

BioCentury | Feb 06, 2006

Clinical News

Alagebrium: Phase IIa discontinued

...hypertension, for which it had been in Phase IIb testing (see BioCentury, June 13, 2005). Alteon...

BioCentury | Feb 06, 2006

Company News

Alteon management update

Alteon Inc. (ALT), Parsippany, N.J. Business: Cardiovascular Resigned: Judith Hedstrom as COO WIR Staff...

BioCentury | Feb 02, 2006

Clinical News

Alteon drops alagebrium in ED

ALT withdrew its IND for the Phase IIa EMERALD trial of alagebrium for erectile dysfunction (ED) and discontinued development in the indication. FDA had placed the trial on clinical hold following a review of preclinical...

BioCentury | Dec 19, 2005

Regulation

Making SOX fit better

...up a tremendous amount of management's time, according to Kenneth Moch, president and CEO of Alteon...

BioCentury | Nov 21, 2005

Clinical News

Alagebrium cardiovascular data

...changing local arterial distensibility. Data were presented at the American Heart Association meeting in Dallas. Alteon...

BioCentury | Nov 21, 2005

Clinical News

Alagebrium: Phase IIa data

...alagebrium for 24 weeks. Data were presented at the American Heart Association meeting in Dallas. Alteon...

BioCentury | Oct 03, 2005

Finance

3Q approvals

...of NDA for Vivitrex to treat alcohol dependence. The PDUFA date is now Dec. 30 Alteon...

BioCentury | Oct 03, 2005

Clinical News

Alagebrium: FDA response received

...crosslink breaker to treat hypertension. The product had been in Phase IIb testing for hypertension. Alteon...

BioCentury | Oct 01, 2005

Clinical News

Alteon's ED trial still on hold

ALT said FDA maintained its clinical hold on the Phase IIa EMERALD trial of alagebrium to treat erectile dysfunction (ED) following a review of additional preclinical toxicity data that were submitted in August. ALT said...

BioCentury | Jul 04, 2005

Finance

2Q approvals

...Amoxicillin Pulsys fails Phase III trial to treat pharyngitis/tonsillitis due to Group A streptococcal infections Alteon...

BioCentury | Jul 04, 2005

Company News

Alteon, Avon Products Inc. deal

...anti-aging products for skin care. ALT will receive an upfront payment and annual license payments. Alteon...

BioCentury | Jun 13, 2005

Finance

Ebb & Flow

...see Cover Story). The PDUFA date for the inhaled cyclosporine is July 14. Clinical milestones Alteon...

BioCentury | Jun 13, 2005

Analyst Picks & Changes

Analyst picks & changes

...& changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 6/10 cls Alteon...

BioCentury | Jun 13, 2005

Clinical News

Alagebrium: Development discontinued

...unlikely to meet the primary endpoint. ALT discontinued the development of alagebrium in this indication. Alteon...

BioCentury | Feb 02, 2009

Company News

Synvista diagnostic news

...Synvista Therapeutics Inc. (AMEX:SYI), Montvale, N.J. Business: Diagnostic Synvista will end its ongoing clinical trials of...
...end its ongoing clinical trials of therapeutics to focus on diagnostics and explore strategic alternatives. Synvista...
...FDA for the Haptochek test kit to identify diabetic patients with haptoglobin 2-2 (Hp2-2) genotype. Synvista...

BioCentury | Jun 11, 2005

Clinical News

ALT drops alagebrium in hypertension

Alteon (ALT) discontinued the Phase IIb SPECTRA trial of alagebrium to treat hypertension and will no longer pursue the indication. An independent review committee determined the trial was unlikely to meet the primary endpoint of...

BioCentury | May 30, 2005

Clinical News

Alagebrium: Interim Phase IIa data

...the American Geriatrics Society meeting and the Society of Geriatric Cardiology meeting, both in Orlando. Alteon...

BioCentury | May 09, 2005

Finance

Ebb & Flow

...of primary insulin-like growth factor-1 deficiency (IGFD). The PDUFA date is Aug. 31. Clinical milestones Alteon...

BioCentury | May 09, 2005

Clinical News

Alteon preclinical data

...hypertension. ALT expects two-thirds of the targeted 250 patients to be enrolled by the mid-year. Alteon...

BioCentury | May 05, 2005

Clinical News

No genotoxicity in alagebrium studies

Alteon (ALT) said interim results from preclinical toxicity studies of alagebrium show that liver alterations previously seen in rats, which led to the suspension of enrollment in three trials, are not caused by genotoxicity pathways,...

BioCentury | Mar 07, 2005

Company News

Ambit management update

...Cancer, Inflammation Hired: Robert deGroof as SVP of development, formerly SVP of scientific affairs at Alteon...

BioCentury | Feb 28, 2005

Finance

Ebb & Flow

...date and MICU hopes to launch it in the first quarter of 2006. Clinical milestones Alteon...

BioCentury | Feb 28, 2005

Clinical News

Alagebrium: Phase II delayed

...trial will continue in the patients already enrolled. Additional preclinical data is due by mid-year. Alteon...

BioCentury | Feb 28, 2005

Clinical News

Alagebrium: Phase IIb delayed

...trial will continue in the patients already enrolled. Additional preclinical data is due by mid-year. Alteon...

BioCentury | Feb 28, 2005

Clinical News

Alagebrium: Phase II delayed

...trial will continue in the patients already enrolled. Additional preclinical data is due by mid-year. Alteon...

BioCentury | Feb 25, 2005

Clinical News

Alteon halts enrollment in alagebrium trials

ALT said it temporarily stopped enrolling new patients in three trials of alagebrium, including two Phase IIa trials in heart failure and erectile dysfunction and a Phase IIb study in hypertension. ALT will continue treating...

BioCentury | Jan 24, 2005

Clinical News

Alagebrium: Started Phase II

...receive 200 mg once-daily alagebrium or placebo in combination with PDE-5 therapy for 16 weeks. Alteon...

BioCentury | Jan 07, 2005

Financial News

Alteon raises $10 million

ALT raised $10 million in a private placement of 9.5 million shares at $1.05. The shares were sold under an existing shelf registration. Rodman & Renshaw was the placement agent. ALT will use the proceeds...

BioCentury | Jan 03, 2005

Clinical News

Alteon preclinical data

...a Phase II trial of the compound to treat erectile dysfunction (ED) in early 2005. Alteon...

BioCentury | Jan 03, 2005

Clinical News

Alagebrium: Phase IIb data

...average reduction of 18 mmHg (p<0.01). Results were published in the American Journal of Hypertension. Alteon...

BioCentury | Jan 03, 2005

Clinical News

Alagebrium: Phase IIb ongoing

...patients will receive once daily alagebrium or placebo in combination with hydrochlorothiazide for 12 weeks. Alteon...

BioCentury | Jan 03, 2005

Clinical News

Alagebrium: Start Phase II

...early 2005 a double-blind, placebo-controlled Phase II trial of alagebrium to treat erectile dysfunction (ED). Alteon...

BioCentury | Dec 20, 2004

Company News

Alteon management update

Alteon Inc. (ALT), Parsippany, N.J. Business: Neurology, Metabolic Promoted: Judith Hedstrom to COO from SVP of corporate development WIR Staff Neurology...

BioCentury | Oct 25, 2004

Clinical News

Alteon preclinical data

...were presented at the International Society for Sexual and Impotence Research meeting in Buenos Aires. Alteon...

BioCentury | Apr 26, 2004

Finance

Ebb & Flow

...second half. R112 is a nasal spray Syk kinase inhibitor that inhibits mast cell activation. Alteon...

BioCentury | Apr 26, 2004

Product Development

Getting it right, more or less

...Last year, Alteon Inc. 's alagebrium (ALT-711) failed in separate Phase II trials in systolic hypertension...

BioCentury | Apr 26, 2004

Clinical News

Alagebrium: Phase II started

...alagebrium (35 mg daily or 210 mg twice daily) for a total of 24 weeks. Alteon...

BioCentury | Apr 20, 2004

Clinical News

Alteon starts heart failure Phase IIa

ALT began a U.S. Phase IIa trial (PEDESTAL) of its alagebrium (formerly ALT-711) in 20 patients with diastolic dysfunction and impaired ejection fraction. The primary endpoints of the open-label trial are quantification of left ventricular...

BioCentury | Mar 29, 2004

Finance

Missing the boat

...the boat Company 3/7/03 MCap MCap Chg % chg 3/7/03price 3/5/04 price Chg % chg Alteon...

BioCentury | Mar 15, 2004

Clinical News

Alagebrium chloride: Phase IIb

...3 daily doses of alagebrium (10, 50, or 150 mg) or placebo for 12 weeks. Alteon...

BioCentury | Mar 10, 2004

Clinical News

Alteon starts ALT-711 Phase IIb

ALT began the U.S., dose-ranging Phase IIb SPECTRA trial of its ALT-711 to treat systolic hypertension in about 390 patients. Following a wash-out period, patients will receive one of three daily doses of ALT-711 (10,...

BioCentury | Mar 01, 2004

Clinical News

ALT-711: Phase IIb

...with or without left ventricular hypertrophy (LVF). All patients also received existing concomitant anti-hypertensive therapy. Alteon...

BioCentury | Feb 16, 2004

Clinical News

ALT-711: Phase II

...After a three-week placebo run-in period, patients will receive ALT-711 twice daily for eight weeks. Alteon...

BioCentury | Feb 11, 2004

Clinical News

Alteon starts ALT-711 Phase II

ALT began a U.S. Phase II trial of its ALT-711 in 25 patients with systolic hypertension. After a three-week placebo run-in period, patients will receive ALT-711 twice daily for 8 weeks. The primary endpoint of...

BioCentury | Oct 06, 2003

Finance

3Q setbacks

...a Phase III trial in coronary artery bypass graft (CABG) surgery with cardiopulmonary bypass (CPB) Alteon...

BioCentury | Jul 21, 2003

Finance

Ebb & Flow

...detects Chlamydia trachomatis and Neisseria gonorrhoeae. GPRO was up $3.02 on the week. Clinical milestones Alteon...

BioCentury | Jul 21, 2003

Analyst Picks & Changes

Analyst picks & changes

Alteon Inc. (ALT), Ramsey, N.J. Business: Cardiovascular Needham & Co. analyst Mark Monane downgraded his rating to "hold" from "buy" after the company's ALT-711 AGE cross-link breaker missed the primary endpoint of a decrease in...

BioCentury | Jul 21, 2003

Clinical News

ALT-711: Phase IIb

...company said assuming positive data from that trial, Phase III trials could begin in 2005. Alteon...

BioCentury | Jul 17, 2003

Clinical News

Alteon misses Phase IIb endpoint

ALT said its ALT-711 advanced glycosylation endproduct (AGE) cross-link breaker failed to significantly lower systolic hypertension compared to placebo in two Phase IIb trials. The double-blind, U.S. SAPPHIRE and SILVER trials enrolled a total of...

BioCentury | Apr 28, 2003

Clinical News

Alteon preclinical data

...particular, ALT-711 reduced the cardiac accumulation of AGEs and increased collagen solubility to normal levels. Alteon...

BioCentury | Apr 07, 2003

Clinical News

ALT-711: Phase IIa

...were more variable than anticipated due to methodology and execution issues (see BioCentury, Jan. 27). Alteon...

BioCentury | Feb 10, 2003

Finance

The sound of silence

...be a pressing challenge under the new order, said Kenneth Moch, president and CEO of Alteon...
...sees a move toward specialization in analysts. "Before, analysts could cover an Amgen and an Alteon,"...

BioCentury | Feb 10, 2003

Finance

Widow & orphan plays?

...Cubist (CBST) 4% 94% 2% $6.30 $179.9 Praecis (PRCS) 19% 70% 11% $3.12 $161.6 ~$100M Alteon...

BioCentury | Jan 27, 2003

Finance

Ebb & Flow

...already is approved to prevent HBV infection upon acute exposure to the virus. Clinical milestones Alteon...

BioCentury | Jan 27, 2003

Product Development

A diamond less rough

...Preliminary results of Alteon Inc. 's Phase IIa DIAMOND trial in diastolic heart failure gave fresh...

BioCentury | Jan 27, 2003

Clinical News

ALT-711: Phase IIa

...mortality. Patients in the trial received 210 mg of ALT-711 twice daily plus current medications. Alteon...

BioCentury | Jan 21, 2003

Clinical News

Alteon Phase IIa ALT-711 data

ALT reported preliminary data from the first 17 patients in the 23-patient Phase IIa DIAMOND trial of its ALT-711 to treat diastolic heart failure (DHF). After 16 weeks, ALT said the compound significantly reduced left...

BioCentury | Jan 06, 2003

Finance

2002 PIPEs

...$25.3 $0.48 -$8.72 -95% Lynx $22.6 $0.41 -$3.62 -90% AVI BioPharma $22.1 $5.00 -$5.92 -54% Alteon...

BioCentury | Jan 06, 2003

Finance

Hunker down

...VERS, Fremont, Calif.) should have Phase III data on its anidulafungin in invasive aspergillosis, and Alteon...

BioCentury | Dec 23, 2002

Analyst Picks & Changes

Analyst picks & changes

Alteon Inc. (ALT), Ramsey, N.J. Business: Cardiovascular, Metabolic W.R. Hambrecht analyst Jason Kantor began coverage with a "buy" and a $6 price target. He expects ALT to report positive data in mid-2003 for its Phase...

BioCentury | Nov 18, 2002

Clinical News

ALT-711: Phase IIb

...pressures). ALT-711 also is in a Phase IIa trial (DIAMOND) to treat diastolic heart failure. Alteon...

BioCentury | Nov 12, 2002

Clinical News

Alteon completes SAPPHIRE enrollment

ALT completed enrollment of 450 patients in its double-blind, placebo-controlled dose-ranging Phase IIb SAPPHIRE trial of ALT-711 to treat systolic hypertension. ALT's compound, which inhibits advanced glycosylation end-product (A.G.E.) crosslinks, also is in the SILVER...

BioCentury | Nov 04, 2002

Analyst Picks & Changes

Analyst picks & changes

Alteon Inc. (ALT), Ramsey, N.J. Business: Cardiovascular, Metabolic Needham & Co. analyst Mark Monane began coverage with a "buy" and a 12-18 month price target of $7. He said the main driver of the stock...

BioCentury | Sep 23, 2002

Clinical News

ALT-711: Phase IIb

...patients with systolic hypertension without left ventricular hypertrophy in its U.S. Phase IIb SAPPHIRE trial. Alteon...